Paroxysmal nocturnal hemoglobinuria medical therapy: Difference between revisions
No edit summary |
|||
| Line 47: | Line 47: | ||
==Medical Therapy== | ==Medical Therapy== | ||
* | === Hematopoietic cell transplantation === | ||
* | * Hematopoietic stem cell transplantation is an important curative therapy for paroxysmal nocturnal hemoglobinuria. | ||
* Stem cell transplantation is usually reserved for the severely affected patients and is indicated for the following type of patients:<ref name="pmid28013015">{{cite journal| author=DeZern AE, Zahurak M, Symons H, Cooke K, Jones RJ, Brodsky RA| title=Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia. | journal=Biol Blood Marrow Transplant | year= 2017 | volume= 23 | issue= 3 | pages= 498-504 | pmid=28013015 | doi=10.1016/j.bbmt.2016.12.628 | pmc=5373094 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28013015 }}</ref> | |||
* | ** Patients with severe aplastic anemia who are HLA matched donor. | ||
** Patients with myelodysplastic syndromes | |||
** | ** Patients who are unresponsive to the anti complement therapy (eculizumab) | ||
* Transplantation related issues:<ref name="pmid22689687">{{cite journal| author=Peffault de Latour R, Schrezenmeier H, Bacigalupo A, Blaise D, de Souza CA, Vigouroux S et al.| title=Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. | journal=Haematologica | year= 2012 | volume= 97 | issue= 11 | pages= 1666-73 | pmid=22689687 | doi=10.3324/haematol.2012.062828 | pmc=3487438 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22689687 }}</ref><ref name="pmid16051736">{{cite journal| author=Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R et al.| title=Diagnosis and management of paroxysmal nocturnal hemoglobinuria. | journal=Blood | year= 2005 | volume= 106 | issue= 12 | pages= 3699-709 | pmid=16051736 | doi=10.1182/blood-2005-04-1717 | pmc=1895106 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16051736 }}</ref> | |||
** Acute Gravt-Versus-Host Disease (GVHD) occurs in almost third of the PNH patients treated with transplant. | |||
** Survival rate of the PNH patients treated with transplantation is from 50% to 60%. | |||
==References== | ==References== | ||
Revision as of 01:21, 22 August 2018
|
Paroxysmal nocturnal hemoglobinuria Microchapters |
|
Differentiating Paroxysmal nocturnal hemoglobinuria from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Paroxysmal nocturnal hemoglobinuria medical therapy On the Web |
|
American Roentgen Ray Society Images of Paroxysmal nocturnal hemoglobinuria medical therapy |
|
Paroxysmal nocturnal hemoglobinuria medical therapy in the news |
|
Blogs on Paroxysmal nocturnal hemoglobinuria medical therapy |
|
Directions to Hospitals Treating Paroxysmal nocturnal hemoglobinuria |
|
Risk calculators and risk factors for Paroxysmal nocturnal hemoglobinuria medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There is no treatment for [disease name]; the mainstay of therapy is supportive care.
OR
Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].
OR
The majority of cases of [disease name] are self-limited and require only supportive care.
OR
[Disease name] is a medical emergency and requires prompt treatment.
OR
The mainstay of treatment for [disease name] is [therapy].
OR The optimal therapy for [malignancy name] depends on the stage at diagnosis.
OR
[Therapy] is recommended among all patients who develop [disease name].
OR
Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
OR
Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
OR
Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
OR
Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
Medical Therapy
Hematopoietic cell transplantation
- Hematopoietic stem cell transplantation is an important curative therapy for paroxysmal nocturnal hemoglobinuria.
- Stem cell transplantation is usually reserved for the severely affected patients and is indicated for the following type of patients:[1]
- Patients with severe aplastic anemia who are HLA matched donor.
- Patients with myelodysplastic syndromes
- Patients who are unresponsive to the anti complement therapy (eculizumab)
- Transplantation related issues:[2][3]
- Acute Gravt-Versus-Host Disease (GVHD) occurs in almost third of the PNH patients treated with transplant.
- Survival rate of the PNH patients treated with transplantation is from 50% to 60%.
References
- ↑ DeZern AE, Zahurak M, Symons H, Cooke K, Jones RJ, Brodsky RA (2017). "Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia". Biol Blood Marrow Transplant. 23 (3): 498–504. doi:10.1016/j.bbmt.2016.12.628. PMC 5373094. PMID 28013015.
- ↑ Peffault de Latour R, Schrezenmeier H, Bacigalupo A, Blaise D, de Souza CA, Vigouroux S; et al. (2012). "Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria". Haematologica. 97 (11): 1666–73. doi:10.3324/haematol.2012.062828. PMC 3487438. PMID 22689687.
- ↑ Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R; et al. (2005). "Diagnosis and management of paroxysmal nocturnal hemoglobinuria". Blood. 106 (12): 3699–709. doi:10.1182/blood-2005-04-1717. PMC 1895106. PMID 16051736.